Uji klinis Glioma di New York
28 studi untuk Glioma mencari peserta di lokasi di New York.
Kota di New York
Teks studi resmi (Bahasa Inggris)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- dan 4 lainnya
Menerima pesertaFase 1/2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Northwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success
- Columbia University Irving Medical Center, New York
- Montefiore Medical Center, The Bronx
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07326566A Study of Mirdametinib in People With Central Nervous System Tumors
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07539441Glioma Developmental and HyperActive Ras Tumor (DHART) Board
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT05489783SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- New York University, New York
Menerima pesertaFase 1
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT04485559Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, New York
- Research Site, New York
Menerima pesertaFase 1/2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05417594Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- New York Presbyterian Hospital-Columbia University Medical Center, New York
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT07486713A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- NYU Langone Health, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07464925A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05188508Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- NYU Langone Health, New York
Menerima peserta
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT06910306MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 1/2
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT06712875Chronic CED of TPT for Recurrent Malignant Glioma
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06666712A Study of 177Lu-PSMA-617 in People With Gliomas
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT07223034Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
- Lenox Hill Brain Tumor Center, New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jun 2026 · NCT05954858Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- Lenox Hill Brain Tumor Center, New York
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jun 2026 · NCT05271240Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
- Lenox Hill Brain Tumor Center, New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jun 2026 · NCT05979064A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- Roswell Park, Buffalo
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT06326411Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Memorial Sloan Kettering, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT06126744Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06810544Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- Lenox Hill Brain Tumor Center, New York
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT02800486DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
- Northwell Health, Lake Success
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mar 2026 · NCT06504381FUS Etoposide for DMG
- Columbia University Irving Medical Center, New York
Menerima pesertaFase 1
Usia 4 hingga 21 · Semua jenis kelamin · Diperbarui 28 Jan 2026 · NCT05762419Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
- NYU Langone Health, New York
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jan 2026 · NCT06829173Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
- University of Rochester, Rochester
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Des 2025 · NCT04543201Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Okt 2025 · NCT00870129Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- Northshore University Hospital, Manhasset
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mar 2025 · NCT01906385Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.